• Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Akebia Therapeutics Inc

+ Add to Watchlist

AX9:GR

9.836 EUR 0.577 5.54%

As of 11:56:33 ET on 11/28/2014.

Snapshot for Akebia Therapeutics Inc (AX9)

Open: 10.387 Day's Range: 9.836 - 10.444 Volume: 0
Previous Close: 10.413 52wk Range: 7.109 - 21.360 1-Yr Rtn: -

Stock Chart for AX9

No chart data available.
  • AX9:GR 10.387
  • 1D
  • 1M
  • 1Y
10.413
Interactive AX9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AX9

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -6.2300
Est. PEG Ratio -
Market Cap (M EUR) 200.07
Shares Outstanding (M) 20.34
30 Day Average Volume 57
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AX9

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AX9

Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the United States.

John P ButlerPresident/CEOJason A AmelloSenior VP/CFO/Treasurer
Brad MaroniSenior VP/Chief Medical OfficerNicole R Hadas "Nikki"VP/General Counsel
More Company Profile & Key Executives for AX9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil